Strategy for the development of the low molecular weight heparin fraction CY 216 in the prevention of postoperative deep vein thromboses in general surgery.
The polymorphism in the composition and actions of heparin and the parallel complexity of the thrombotic process have led to the design of a cautious, methodical, and pragmatic program of development of the first low molecular heparin fraction presently available in France (CY 216). The main idea was always to present the objective observation of facts and to reject any theoretical construction. After many stages, the value of this fraction in this indication, which appears as safe as possible but more effective than unfractionated heparin, has become obvious.
Toulemonde
F
F
Institut Choay, Paris, France.
D000818:Animals; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents / Q000266:history / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000266:history / Q000493:pharmacokinetics / Q000627:therapeutic use*; D049673:History, 20th Century; D006801:Humans; D010314:Partial Thromboplastin Time; D011183:Postoperative Complications / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic; D013924:Thrombophlebitis / Q000209:etiology / Q000517:prevention & control*
D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D006493:Heparin